Search results
Showing 7901 to 7950 of 8140 results
Safeguarding in care homes, adoption in looked after children and young people, and support for carers are among social care topics being considered for new NICE guidance and quality standards.
Diagnose and treat Lyme disease if bull's eye rash is present, says NICE
People presenting erythema migrans, the characteristic skin rash associated with Lyme disease, can be diagnosed and treated without the need for blood tests, NICE has said in a final quality standard published today.
Health professionals can consider digital and mobile interventions as a supplement to regular services to support behaviour change in people at risk of developing chronic conditions.
Four digital technologies that can help children and young people with mild to moderate symptoms of anxiety or low mood have been recommended for use in the NHS once they achieve regulatory approval.
A magnetic marker liquid injected into people with invasive breast cancer will help surgeons discover if the cancer has spread, after the technology was recommended in draft NICE guidance.
NICE recommends new 'chemotherapy-free' treatment for lymphoma
A new treatment option for patients with previously treated follicular lymphoma (grade 1 to 3A) has been approved by NICE.
More than 1,000 people each year will benefit from NICE's recommendation
NICE recommends new diagnostic devices for men with suspected prostate cancer in draft guidance
Four new diagnostic devices for men with suspected prostate cancer, which reduce the chances of biopsy related sepsis, have been recommended for use by NICE.
Thousands of people living with obesity are set to benefit from a new drug which has helped those using it to reduce their weight by more than 10 per cent.
NICE recommends new drug osimertinib for hundreds of people with lung cancer
Hundreds of people with lung cancer will now have access to new drug osimertinib, also known as Tagrisso, after NICE says it should be made available on the Cancer Drugs Fund (CDF).
Hundreds of people with a rare blood disorder have access to a new treatment regimen following draft guidance from NICE.
All eligibility criteria must be met for Liraglutide to be offered
NICE recommends offering app-based treatment for people with insomnia instead of sleeping pills
Hundreds of thousands of people suffering from insomnia who would usually be prescribed sleeping pills could be offered an app-based treatment programme instead, NICE has said.
NICE recommends offering PrEP to people at high risk of HIV for first time
People at the highest risk of catching HIV should be offered Pre Exposure Prophylaxis (PrEP), NICE has recommended for the first time.
NICE recommends Piqray and Trodelvy, maintaining 100% approvals of breast cancer drugs since 2018
An agreement with the companies on the price of 2 breast cancer treatments, Piqray and Trodelvy, has paved the way for NICE to be able to make them available immediately to around 3,450 people on the NHS and maintaining NICE’s 100% approval rate of breast cancer drugs since 2018.
NICE recommends potentially life-changing treatment for people with short bowel syndrome
A potentially life-changing treatment has been recommended for people with short bowel syndrome who are aged 1 year and above after NICE published final draft guidance today (01 June 2022)
People with chronic primary pain should be offered a range of treatments to help them manage their condition, NICE has said in its guideline on the assessment and management of chronic pain published today (7 April).
NICE recommends rivaroxaban to prevent blood clots in patients who have had a heart attack
Rivaroxaban (Xarelto), in combination with clopidogrel and aspirin, or with aspirin alone, can now be used as an option for preventing blood clots in people who have had an acute coronary syndrome, following latest guidance.
NICE recommends several treatment options to help thousands with moderate rheumatoid arthritis
Around 25,000 people with moderate rheumatoid arthritis that has not responded to conventional therapies are set to benefit from the recommendations announced today
NICE recommends step-change targeted treatment for people with early breast cancer
Around 4,000 people are set to benefit from a step-change in treatment for early breast cancer following today’s (17 June 2022) provisional approval by NICE of abemaciclib in combination with hormone therapy as an option after surgery.
NICE recommends treatment for people with juvenile idiopathic arthritis
NICE has today (9 September 2021) published final draft guidance which recommends tofacitinib (also known as Xeljanz and made by Pfizer) as an option for treating active polyarticular juvenile arthritis and juvenile psoriatic arthritis in people 2 years and older.
NICE recommends treatment for type of small-cell lung cancer
A new treatment option for patients with extensive-stage small-cell lung cancer has been approved by NICE.
NICE recommends treatment options for severe pregnancy sickness in new draft guidance
Nausea and vomiting, often referred to as morning sickness, is common in pregnancy. Close to 80% of pregnant women experience these symptoms, with most conditions improving or stopping completely by around 16 to 20 weeks.
Ahead of the roundtable meeting on 18 October, NICE has today (12 October 2021) released details of the agenda and how the meeting will be run.
NICE recommends routine funding for Duchenne muscular dystrophy gene therapy ataluren
NICE has today (22 February 2023) published final guidance which recommends ataluren (also called Translarna and made by PTC Therapeutics) for treating Duchenne muscular dystrophy (DMD) caused by a nonsense mutation.
NICE says new triple negative advanced breast cancer drug too expensive for NHS use
NICE has today, 7 April 2022, issued draft guidance which does not recommend sacituzumab govitecan for treating locally advanced or metastatic triple negative breast cancer.
NICE has today (16 February 2023) issued draft guidance for public consultation which does not recommend Evusheld for preventing COVID-19 in adults who are unlikely to have an adequate immune response to COVID-19 vaccination, or who can’t be vaccinated.
Changes to the way medicines and other health technologies are evaluated by NICE for use in the NHS were approved by its Board yesterday (19 January 2022).
NICE, the Scottish Intercollegiate Guidelines Network (SIGN) and the Royal College of General Practitioners (RCGP) have today (30 October 2020) given more details about the forthcoming guideline on post-COVID syndrome.
NICE recommends cutting-edge therapy for young people with blood cancer
NICE has recommended a pioneering cancer treatment, CART-cell therapy, for people under the age of 25 with leukaemia.
People with a rare condition that steadily worsens often leaving them dependent on a wheelchair and with shortened life expectancy, can now benefit from the first treatment to slow its progression.
NICE recommends Enhertu for more people with advanced breast cancer
Hundreds more people eligible for breast cancer drug Enhertu as NICE recommends it for earlier stage disease, in final draft guidance.
People with a rare blood disorder have access to a new treatment following draft guidance from NICE.
NICE recommends first treatment in two decades for sickle cell disease
Hundreds of people will be eligible for a new treatment for sickle cell disease following draft guidance published today (5 October).
NICE recommends genetic test to prevent newborn babies going deaf
A genetic test to establish if a newborn baby is vulnerable to deafness if treated with a commonly used antibiotic has been recommended by NICE in final guidance.
NICE recommends offering women induced labour earlier in new draft guidance
Women should be offered induced labour earlier than previously advised to make birth safer for them and their babies, according to draft guidelines published by NICE today (25 May 2021). The updated recommendations strengthen previous advice in the light of new evidence on induction timings.
NICE recommends innovative treatment for severe blood disorder for NHS use
Caplacizumab, with plasma exchange and immunosuppression, will be used to treat acute acquired thrombotic thrombocytopenic purpura.
The first and currently only gene therapy for children with an ultra-rare genetic disorder has been recommended by NICE in final draft guidance published today (23 March 2023).
NICE publishes rapid COVID-19 guidelines on chronic kidney disease and interstitial lung disease
NICE has today (15 May) published 2 new rapid COVID-19 guidelines. The first is on chronic kidney disease (CKD) and the second on interstitial lung disease.
The new guidelines cover the provision of radiotherapy services and bone marrow transplant during the COVID-19 pandemic.
One year on from the first national lockdown, NICE has today (23 March) published a single guideline for the management of COVID-19 in children and adults.
NICE publishes updated clinical guideline on the diagnosis and management of atrial fibrillation
NICE has today (27 April 2021) published its updated guideline on the diagnosis and management of atrial fibrillation (AF).
NICE has published 2 new rapid COVID-19 guidelines on the care of patients with suspected and confirmed COVID-19.
NICE has today, 30 January 2020, published a simple guide to the way we develop our guidance and standards.
NICE is calling for early identification of asymptomatic and symptomatic peripheral arterial disease to help improve the care of patients with the condition.
NICE, RCGP and SIGN publish guideline on managing the long-term effects of COVID-19
NICE, the Royal College of General Practitioners (RCGP) and the Scottish Intercollegiate Guidelines Network (SIGN) have today (18 December 2020) published a guideline on the management of the long-term effects of COVID-19 (also known as Long COVID).
NICE reaches important milestone in the UK's efforts to tackle antimicrobial resistance.
Two new antimicrobial drugs - cefiderocol and ceftazidime–avibactam - are close to becoming the first to be made available as part of the UK’s innovative subscription-style payment model after NICE today (Tuesday, 12 April 2022) published draft guidance estimating their value to the NHS.
NICE recommend dapagliflozin for people with chronic kidney disease
Dapagliflozin belongs to a group of medicines called ‘sodium glucose co-transporter-2 (SGLT2) inhibitors. It is the first SGLT2 inhibitor to be recommended through NICE’s technology appraisal process for CKD.
NICE recommended weight-loss drug to be made available in specialist NHS services
Thousands of people will soon be able to be prescribed a drug to help them lose weight as part of their treatment in an NHS specialist weight management service.
Three treatments for COVID have been recommended in draft NICE guidance released today for public consultation.